An Open-label, Multi-center, Phase I/II Study to Assess Safety, Tolerability and Efficacy of DFT383 in Pediatric Participants With Nephropathic Cystinosis
Latest Information Update: 11 Apr 2025
At a glance
- Drugs DFT 383 (Primary) ; Mercaptamine
- Indications Nephropathic cystinosis
- Focus Adverse reactions; Therapeutic Use
- Acronyms CYStem
- 11 Apr 2025 New trial record